Evaluating a new ultrasound system for treating breast cancer

A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

This study is testing a new ultrasound treatment for women with invasive breast cancer to see if it can safely shrink tumors before surgery.

Quick facts

• Phase: EARLY_PHASE1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: University of Utah (other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (Salt Lake City, Utah)
• Trial ID: NCT05291507 on ClinicalTrials.gov

What this trial studies

This open-label, single-arm feasibility study investigates the Muse Magnetic Resonance Guided Focused Ultrasound (MRgFUS) System in women with invasive breast cancer. Participants will undergo partial ablation of up to 50% of their tumor, followed by standard surgical resection to ensure that viable tissue is retained for further testing. The study aims to assess the safety, tolerability, and efficacy of this innovative treatment approach through imaging correlation, histological evaluation, and patient-reported outcomes. The design allows for timely tumor resection while exploring a novel therapeutic option.

Who should consider this trial

Good fit: Ideal candidates are female patients aged 18 and older with invasive breast cancer who are scheduled for surgery.

Not a fit: Patients with non-invasive breast cancer or those who are not surgical candidates may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a less invasive treatment option for breast cancer patients, potentially improving outcomes and preserving more healthy tissue.

How similar studies have performed: While focused ultrasound is a growing field, this specific application in breast cancer treatment is relatively novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

* Subject is able to speak and understand English.
* Female subjects 18 years of age or older with invasive breast cancer undergoing surgery
* ECOG \< 2.
* ASA (American Society of Anesthesiologists) Physical Status Classification Scale assessment of I-II.
* Adequate breast size for MUSE device assessed by physician prior to study enrollment.
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
* Adequate Renal Function defined as an eGFR \> 30 mL/min/1.73.
* Female subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.
* Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization (i.e. bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). The post-menopausal status will be defined as having been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:

  * Women \< 50 years of age:

    ---Amenorrhoeic for ≥ 12 months following cessation of exogenous hormonal treatments; and

    ----Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.
  * Women ≥ 50 years of age:

    * Amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments; or
    * Had radiation-induced menopause with last menses \>1 year ago; or
    * Had chemotherapy-induced menopause with last menses \>1 year ago.

Exclusion Criteria:

* Receiving other investigational agents at the time of study registration.
* Prior systemic anti-cancer therapy or any investigational therapy for neoadjuvant treatment of breast cancer.
* Prior radiation therapy to the ipsilateral breast or radiation whose field(s) encompassed the breast within which the current diagnosis of cancer is made.
* The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, or bladder or of the cervix). Low risk malignancies may be allowed after discussion with PI and medical monitor.
* Women with breast implants
* Pregnant or lactating women
* Inability to lie prone for 90 minutes as reported by patient or determined by investigator assessment.
* Known prior adverse reaction or allergy to commonly used sedatives (i.e. versed, propofol) (NCI CTCAE v5.0 Grade ≥ 3).
* Known prior adverse reaction or allergy to gadolinium contrast (NCI CTCAE v5.0 Grade ≥ 3).
* Contraindication to MRI as determined by treating physician or patient response on MRI patient history and safety questionnaire (Appendix 4)
* Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.

Additional Exclusion Criteria for Cohort 1 patients only

* Patient's tumor is grade 3 as determined in consultation with pathologist and treating physician.
* The amount of invasive tumor in the core biopsy specimen is small as determined in consultation with pathologist and treating physician.
* Core biopsy result is equivocal for HER2 after testing by both in situ hybridization and immunohistochemistry.
* There is doubt about the handling of the core biopsy specimen (long ischemic time, short time in fixative, different fixative), or the test is suspected by the pathologist to be negative on the basis of testing error.

Where this trial is running

Salt Lake City, Utah

• Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah, United States (RECRUITING)

Study contacts

• Principal investigator: Cindy Matsen, MD — Huntsman Cancer Institute
• Study coordinator: Janna Espinosa

Conditions: Breast Cancer